Premium
Model‐Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First‐Line Anaplastic Lymphoma Kinase + Non‐Small Cell Lung Cancer
Author(s) -
Morcos Peter N.,
Liu Jiang,
Blumenthal Gideon M.,
Zhao Hong
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1340
Subject(s) - alectinib , anaplastic lymphoma kinase , crizotinib , medicine , lung cancer , drug , drug development , lymphoma , alk inhibitor , oncology , pharmacology , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom